{
  "directed": true,
  "multigraph": true,
  "graph": {
    "pybel_version": "0.13.0",
    "document_metadata": {
      "copyright": "Copyright © 2018 Fraunhofer Institute SCAI, All rights reserved.",
      "licenses": "CC BY 4.0",
      "contact": "charles.hoyt@scai.fraunhofer.de",
      "name": "dinopoulou2013",
      "version": "1.0.0",
      "authors": "Lingling Xu",
      "description": ""
    },
    "namespace_url": {
      "CHEBI": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/chebi-names.belns",
      "DRUGBANK": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/drugbank-names.belns",
      "ECCODE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/ec-code.belns",
      "HBP": "https://raw.githubusercontent.com/pharmacome/terminology/3074b85b858455d8eeb76cfcdef685ced19bbe11/export/hbp-names.belns",
      "HGNC": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/hgnc-names.belns",
      "HGNCGENEFAMILY": "https://raw.githubusercontent.com/pharmacome/terminology/3074b85b858455d8eeb76cfcdef685ced19bbe11/external/hgnc.genefamily-names.belns",
      "GO": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/go-names.belns",
      "INTERPRO": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/interpro-names.belns",
      "MESH": "https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/mesh-names.belns",
      "MGI": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/mgi-names.belns",
      "MIRBASE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/mirbase-names.belns",
      "NCBIGENE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/entrez.belns",
      "PFAM": "https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/pfam-names.belns",
      "RGD": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/rgd-names.belns",
      "FPLX": "https://raw.githubusercontent.com/sorgerlab/famplex/e8ae9926ff95266032cb74f77973c84939bffbeb/export/famplex.belns",
      "CTO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/clinical-trial-ontology/clinical-trial-ontology-1.0.0.belns",
      "DO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/disease-ontology/disease-ontology-20170725.belns",
      "HP": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hp/hp-20171108.belns",
      "SCOMP": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-named-complexes/selventa-named-complexes-20170725.belns",
      "SFAM": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-protein-families/selventa-protein-families-20170725.belns"
    },
    "namespace_pattern": {
      "DBSNP": "rs[0-9]+",
      "TAXONOMY": "^\\d+$",
      "UNIPROT": "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\\.\\d+)?$",
      "PUBCHEM": "^\\d+$"
    },
    "namespaces_uncached": [],
    "annotation_url": {
      "Anatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno",
      "CellLine": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno",
      "CellStructure": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno",
      "Cell": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno",
      "Confidence": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno",
      "Disease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno",
      "Gender": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno",
      "MeSHAnatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno",
      "MeSHDisease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno",
      "Subgraph": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno",
      "TextLocation": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"
    },
    "annotation_pattern": {
      "Species": "^\\d+$"
    },
    "annotation_list": {},
    "path": "/Users/cthoyt/dev/knowledge/hbp_knowledge/dinopoulou2013.bel"
  },
  "nodes": [
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Embryonic Structures",
      "id": "421861e2de7af8e045ee78999f03126bf71bd8459cc2d6585a4d027780af5f84d1035dc5fc38dc40dbdebc610180e9744ce1ba916050b23f585f0b44a4710000"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Blastocyst",
      "id": "e0d7ba0f767b47cb1fe6d7f90e11f6a3abf0740e79c19bd92df5206867f487857558647e8f4511573f972d0263edca59346c8e20eb9dd17de66104d033ac0a3b"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Estradiol",
      "id": "8034004b23596902def9aaca86fc2ec4178074e9c2322c9e541992ab6617a07a806b884765af7c56a49c9cfc916ab4646939d509eecaa4be34a131f61f4e16eb"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Morula",
      "id": "a7ac2403fb44769e34d27b00e588efbd9ae7fff902976ff9368d06a24c9c71410d4ce380723d94ad73536b2b7f660391440e64d31379ae2d8f7cc2d03fd6353c"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Progesterone",
      "id": "e344178489ffcc78f0842683c8d76625b5c1016c4b7bb9954f4bf130abab1abecd0e91cda090294b65520fba77322ca641880ed1fa294f4124785227e274904c"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "antalarmin",
      "id": "b0b5b41a144782eec03211e413d4a3611b38c87f77cafa1af765152343f903703455ce9fcaaf62400084ba460c648619ed05dd43b76be676001d5351949607f5"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CGB3",
      "id": "b7fa4642c7c6fd6948dc8eb37b7357a8b230eb4f5237e822a9598e142ebfa6564e56a9e75429b25b42e1d8d3b5f1e6ee4f719164bc8aedf4bc79ec0b1d84484b"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Crh",
      "id": "296d5df4386b36079c00f57f90a87484cc714181f51e7e7a6bbe9cfdaa6a623931e5cb22ff8f471d2923e0d61de1dd75b5bf546390456d41fd018375d5bb5e33"
    }
  ],
  "links": [
    {
      "line": 82,
      "relation": "increases",
      "evidence": "At all embryo stages, significant differences were noted between the CRH 10􏰁7 and control groups as well as be- tween the CRH 10􏰁7 and CRH 10􏰁7/antalarmin 10􏰁6 groups, with the rates being lower in the former. ",
      "citation": {
        "type": "PubMed",
        "reference": "23211705"
      },
      "source": 5,
      "target": 0,
      "key": "33cda19503779861a3b377df7d06ce1fa61a171033190d7f91324e5c30010e0a172caf8c9700715822c428a6e356446629f656ce3f2b1f30fa7b7c13f5d37bda"
    },
    {
      "line": 85,
      "relation": "increases",
      "evidence": "With regard to the morula/blastocyst stage, the rates in the CRH 10􏰁7 group were lower compared with the control (P 􏰄 0.003) and lower compared with the CRH 10􏰁7/antalarmin 10􏰁6 group (P 􏰃 0.001) (Table 2).",
      "citation": {
        "type": "PubMed",
        "reference": "23211705"
      },
      "source": 5,
      "target": 3,
      "key": "0e4a75da8ce14072ce39e66b1eae4cec16ba67bb44dbb28bafbf4779ae4781fb293b198df60e302a59df75a31847308c62d1afd58bd6886f3037c681692fd4e1"
    },
    {
      "line": 86,
      "relation": "increases",
      "evidence": "With regard to the morula/blastocyst stage, the rates in the CRH 10􏰁7 group were lower compared with the control (P 􏰄 0.003) and lower compared with the CRH 10􏰁7/antalarmin 10􏰁6 group (P 􏰃 0.001) (Table 2).",
      "citation": {
        "type": "PubMed",
        "reference": "23211705"
      },
      "source": 5,
      "target": 1,
      "key": "578c9991d681ac35db1407ee3f99c4f506f15b38b113865b5011af6ca18d905ee672f704825c729730fcabc196e04f653cbd0dbedb73fa4f5ad5b909187a17f9"
    },
    {
      "line": 90,
      "relation": "decreases",
      "evidence": "Interestingly, the addition of a 10-fold excess of the CRH-R1 antagonist, antalarmin, overcame the negative effect of CRH on estradiol release (d 5, P 􏰄 0.009; d 7, P 􏰄 0.010; d 9, P 􏰃 0.001; and d 11, P 􏰄 0.002), indicating that the suppressive effect of CRH was receptor mediated (Fig. 1).",
      "citation": {
        "type": "PubMed",
        "reference": "23211705"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 5,
      "target": 7,
      "key": "31f04b65777b1b5dd3eba368e7040babdd74e598dc8ef8b2c6661e60ae2d48b1d86769df4a6b035c9f4f331fd28541d1316595e7975a919fad9c6739e14ca3c0"
    },
    {
      "line": 94,
      "relation": "decreases",
      "evidence": "The addition of the CRH-R1 an- tagonist antalarmin in a 10-fold higher concentration compared with that of CRH overcame the effect of CRH on beta􏰇-hCG release (d 11 beta􏰇-hCG 185.6 􏰅 6.087 mIU/ml, P 􏰃 0.001) indicating that the suppressive effect of CRH was recep- tor mediated (Fig. 3).",
      "citation": {
        "type": "PubMed",
        "reference": "23211705"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 5,
      "target": 7,
      "key": "b2630e996ba4b77d322ffa7e4a5ebc70eabac64c38119fb0cd7664ea66efe5008034510fd5fe068c9b3953ba932acdc0f1e99cc8ff15fbd2bf640f5977fb5201"
    },
    {
      "line": 102,
      "relation": "decreases",
      "evidence": "The addition of a 10-fold excess of the CRH-R1 antagonist antalarmin reversed the negative ef- fect of CRH on progesterone release (d 11 progesterone 0.712 􏰅 0.004 ng/ml, P 􏰃 0.001), suggesting that the suppressive effect of CRH was receptor mediated (Fig. 2).",
      "citation": {
        "type": "PubMed",
        "reference": "23211705"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 5,
      "target": 7,
      "key": "c87c9af675313445513be886e44edfe13c24ff50b270228ea621bf4e2227f55c1444a5962938055c9768da8a0e4b53fbd98445bedcfadbb19e501863673a48bd"
    },
    {
      "line": 109,
      "relation": "decreases",
      "evidence": "The addition of the CRH-R1 an- tagonist antalarmin in a 10-fold higher concentration compared with that of CRH overcame the effect of CRH on 􏰇-hCG release (d 11 beta􏰇-hCG 185.6 􏰅 6.087 mIU/ml, P 􏰃 0.001) indicating that the suppressive effect of CRH was recep- tor mediated (Fig. 3).",
      "citation": {
        "type": "PubMed",
        "reference": "23211705"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 5,
      "target": 7,
      "key": "8c43e5c5bcce10000456f2acce5ff7bd863f9c435861c72411b3aa76feb666339677b785eda48caaabcab6b42032a7e24df58c40c57e1e555a949198aaf5df05"
    },
    {
      "line": 110,
      "relation": "regulates",
      "evidence": "The addition of the CRH-R1 an- tagonist antalarmin in a 10-fold higher concentration compared with that of CRH overcame the effect of CRH on 􏰇-hCG release (d 11 beta􏰇-hCG 185.6 􏰅 6.087 mIU/ml, P 􏰃 0.001) indicating that the suppressive effect of CRH was recep- tor mediated (Fig. 3).",
      "citation": {
        "type": "PubMed",
        "reference": "23211705"
      },
      "source": 5,
      "target": 7,
      "key": "95f85a182ab35e0c37d3b09ad6ec34603887fe5f4f3d6b512eb4ab60b40d49bc6dc3eaaa4796f63a9999dafda603e80c7c0e725870db7cb5a5c221d1328a9b17"
    },
    {
      "line": 89,
      "relation": "decreases",
      "evidence": "Interestingly, the addition of a 10-fold excess of the CRH-R1 antagonist, antalarmin, overcame the negative effect of CRH on estradiol release (d 5, P 􏰄 0.009; d 7, P 􏰄 0.010; d 9, P 􏰃 0.001; and d 11, P 􏰄 0.002), indicating that the suppressive effect of CRH was receptor mediated (Fig. 1).",
      "citation": {
        "type": "PubMed",
        "reference": "23211705"
      },
      "source": 7,
      "target": 2,
      "key": "c87d103116dd5374f9afe4ade2eab7d55b540bd05573f59a820e7f0edb361ded69961daaadf9a10dac7650eb1b87976d368ac26bac10fc2d2f9b791b807a1bdb"
    },
    {
      "line": 93,
      "relation": "regulates",
      "evidence": "The addition of the CRH-R1 an- tagonist antalarmin in a 10-fold higher concentration compared with that of CRH overcame the effect of CRH on beta􏰇-hCG release (d 11 beta􏰇-hCG 185.6 􏰅 6.087 mIU/ml, P 􏰃 0.001) indicating that the suppressive effect of CRH was recep- tor mediated (Fig. 3).",
      "citation": {
        "type": "PubMed",
        "reference": "23211705"
      },
      "source": 7,
      "target": 6,
      "key": "a167238a0a1b4588ba6f183049d2389ed973b26457d535198a20c7940e99de296ad0d42f162385838c36ea5bbf440e8d9a13fd27b944b94759a7c26ffe471e44"
    },
    {
      "line": 106,
      "relation": "decreases",
      "evidence": "In the CRH 10􏰁7 mol/liter group, the amount of beta􏰇-hCG measured in the culture medium was elevated but to a lesser extent compared with the control group (d 11 􏰇-hCG 6.05 􏰅 0.077 mIU/ml, P 􏰃 0.001). ",
      "citation": {
        "type": "PubMed",
        "reference": "23211705"
      },
      "source": 7,
      "target": 6,
      "key": "416ffc18916f021befc428aeda3021cb8cd3497baac172bc924f227a5c3c27798019a32020f8487471dc5460d95d557fa73a9c2cf0f04e0dea62553072919046"
    },
    {
      "line": 97,
      "relation": "causesNoChange",
      "evidence": "Notably, CRH did not affect the amount of progesterone released into the incubation medium up to d 9, whereas it suppressed pro- gesterone levels on d 11 (d 11 progesterone 0.030 􏰅 0.000 ng/ml, P 􏰃 0.001). ",
      "citation": {
        "type": "PubMed",
        "reference": "23211705"
      },
      "source": 7,
      "target": 4,
      "key": "01a97bd19ff8a2c2929eb6e72209dfebf9f9773fd47a10bc6f5f659822639cf9c1b34bea3339ef2b18febdcbdbced238ac242940f06dac8b49e4ff70e3fba48d"
    },
    {
      "line": 98,
      "relation": "decreases",
      "evidence": "Notably, CRH did not affect the amount of progesterone released into the incubation medium up to d 9, whereas it suppressed pro- gesterone levels on d 11 (d 11 progesterone 0.030 􏰅 0.000 ng/ml, P 􏰃 0.001). ",
      "citation": {
        "type": "PubMed",
        "reference": "23211705"
      },
      "source": 7,
      "target": 4,
      "key": "833c393a60dc3238c9456c3dd17f791048be3b09e2b28a37731a1040a6860d1ec2aefabcc30316bcba95ebb9bf5a95a20560f1f912630e9c10576020108cd443"
    },
    {
      "line": 103,
      "relation": "decreases",
      "evidence": "The addition of a 10-fold excess of the CRH-R1 antagonist antalarmin reversed the negative ef- fect of CRH on progesterone release (d 11 progesterone 0.712 􏰅 0.004 ng/ml, P 􏰃 0.001), suggesting that the suppressive effect of CRH was receptor mediated (Fig. 2).",
      "citation": {
        "type": "PubMed",
        "reference": "23211705"
      },
      "source": 7,
      "target": 4,
      "key": "505f4d5c33e030a02a8d2e369cdea89f456f153aa94f74eebc81466062043b0b824675c80eae7aff63e28c2b584fcbbbdefa1340aa89e8b56f8daa7b4c9859a6"
    }
  ]
}